

THE LANCET Microbe

Supplementary appendix 3

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Sharma AK, Verma H, Estivariz CF, et al. Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial. *Lancet Microbe* 2023; published online Sept 26. [https://doi.org/10.1016/S2666-5247\(23\)00215-X](https://doi.org/10.1016/S2666-5247(23)00215-X).

Table: Adverse events by study arms

Final Diagnosis	Previous IPV	No previous IPV
ARI	7	14
Undifferentiated fever	6	0
Diarrhea/Vomiting	3	16
Acute Pharyngitis	1	4
Local Site reaction	1	0
Nonspecific abdominal pain	1	0
Rashes	1	4
Red eyes	1	0
Undetermined leg pain	1	0
Undifferentiated fever	0	2
Acute wheezing in a recurrent wheezer	0	1
Vomiting	1	0
DSMB report on AEs		
Not related	0	0
Unlikely	22	41
Possibly	0	0
Probably	1	0
Definitely related	0	0
AEFI Class		
Vaccine product related	1	0
Vaccine quality defect related	0	0
Immunization error related	0	0
Immunization anxiety related	0	0
Coincidental event	22	41
Serious Adverse Event (SAE)	-	<p>Onset date: 2 Feb 2019 Stop date: 13 Feb 2019 Last day of study intervention: 1 Feb 2019 Not related to intervention; resolved without sequelae; severe pneumonia requiring hospitalization; coincidental event</p>